89891-77-0 Usage
Uses
Used in Pharmaceutical Industry:
2,3-Quinoxalinedione, 6,7-dibromo-1,4-dihydrois used as a pharmacological agent for its anti-inflammatory properties, helping to reduce inflammation in various conditions. Its ability to modulate inflammatory responses makes it a candidate for the development of drugs targeting inflammatory disorders.
Used in Antiviral Applications:
In the field of antiviral research, 2,3-Quinoxalinedione, 6,7-dibromo-1,4-dihydrois utilized for its potential to inhibit viral replication and activity, offering a possible treatment approach for viral infections.
Used in Neurodegenerative Disease Treatment:
2,3-Quinoxalinedione, 6,7-dibromo-1,4-dihydrois also used in the exploration of treatments for neurodegenerative diseases, given its potential neuroprotective effects and ability to mitigate disease progression.
Used in Oncology:
2,3-Quinoxalinedione, 6,7-dibromo-1,4-dihydrois employed in cancer research for its potential anticancer properties, with ongoing studies investigating its efficacy against various types of cancer and its mechanisms of action in inhibiting tumor growth and proliferation.
Check Digit Verification of cas no
The CAS Registry Mumber 89891-77-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,8,9 and 1 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 89891-77:
(7*8)+(6*9)+(5*8)+(4*9)+(3*1)+(2*7)+(1*7)=210
210 % 10 = 0
So 89891-77-0 is a valid CAS Registry Number.
89891-77-0Relevant academic research and scientific papers
Glycine receptor antagonists and the use thereof
-
, (2008/06/13)
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.
